Supercharged immune cells take on tough lupus cases

NCT ID NCT07233642

Recruiting now Disease control Sponsor: The Children's Hospital of Zhejiang University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new 'ultra-fast' version of CAR-T cell therapy for people with severe lupus that hasn't improved with standard treatments. The therapy uses a patient's own immune cells, modified to target and attack faulty immune cells driving the disease. The study will enroll 18 participants to check safety and see if it can reduce lupus disease activity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CD19-targeted CAR-T cells (a type of immune cell therapy)
What this could lead to: If successful, this could offer a new treatment option for people with severe lupus that hasn't responded to standard therapies.
What could go wrong: This is a very early Phase 1 trial with only 18 participants, so safety and effectiveness are not yet proven. CAR-T therapy can cause serious side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SYSTEMIC LUPUS ERYTHEMATOSUS

Contacts and locations

Locations

Children's Hospital of Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, 310052, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.